| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10486104 | Value in Health | 2015 | 6 Pages |
Abstract
BRA metrics can be useful for identifying net favorability when applied to prospective monitoring of a new drug versus an alternative drug. INB-based approaches similarly outperform unweighted NNT|NNH approaches. Time to alerting was similar across approaches.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Joshua J. PharmD, ScD, Mehdi PhD, Niteesh K. MD, PhD, Katsiaryna PharmD, MS, Kristijan H. PhD, Diane PhD, James R. Rogers, Sebastian MD, ScD,